First Subject to Receive Dosing in the Second Week of July
Caregen, a peptide-based biotechnology company, has initiated a clinical trial targeting lean obesity with its proprietary GLP-1 analog peptide, Coglutide.
According to Caregen on July 3, this clinical trial will involve 200 adult men (with a body fat percentage of 25% or higher) and women (with a body fat percentage of 28% or higher) whose body mass index (BMI) falls within the normal range (22?26). The trial will be conducted at six clinical sites in India, all of which have completed IRB (Institutional Review Board) approval. The first subject is scheduled to receive dosing in the second week of July.
Through this clinical trial, Caregen plans to develop Coglutide as a health functional food, commercializing it as a wellness solution that anyone can easily consume in daily life. Coglutide focuses on key functions such as improving body fat percentage, appetite control, and metabolic balance. It can be taken not only by those with lean obesity?individuals with high body fat but normal weight?but also by anyone seeking short-term weight loss.
Previously, Caregen successfully completed a clinical trial of Coglutide under the same conditions as liraglutide (Saxenda) and semaglutide (Wegovy), involving 100 patients with obesity and type 2 diabetes. The statistical analysis of this trial is currently in its final stages.
The global population of individuals with lean obesity?those with normal weight but increased visceral fat or metabolic abnormalities?is rapidly increasing. The medical community classifies these individuals as a high-risk group for metabolic diseases. In advanced countries such as the United States, 10?22% of the total population falls into the lean obesity category, with particularly high prevalence among women and young to middle-aged adults.
The launch of this clinical trial targeting individuals with normal BMI is regarded as a symbolic milestone demonstrating the scalability and commercial viability of Caregen’s peptide technology. Caregen is rapidly transitioning from a business model centered on medical devices and cosmetics to a platform company encompassing health functional foods and global over-the-counter pharmaceutical channels.
Jung Yongji, CEO of Caregen, stated, "Coglutide is designed to be an everyday weight management solution that anyone can easily take anytime and anywhere. Our ultimate goal is to help improve the quality of life for everyone pursuing a healthy lifestyle."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
